Milestone Pharmaceuticals to Join Jefferies Global Healthcare Conference

Milestone Pharmaceuticals Inc., a biopharmaceutical company listed on Nasdaq under the ticker symbol MIST, has announced that its management team will attend the Jefferies Global Healthcare Conference. This event will take place in New York City, NY, from June 4th to 6th, 2024. Notably, Milestone Pharmaceuticals will feature in a Fireside Chat on June 6th at 11:30 AM EDT. A webcast of this session will be available for live viewing and replay for about 90 days post-presentation on Milestone’s official website.

Milestone Pharmaceuticals is dedicated to developing and commercializing innovative cardiovascular treatments aimed at enhancing the lives of individuals dealing with complex and severe heart conditions. The company’s mission focuses on identifying unmet patient needs and elevating the patient care experience. This commitment has driven the development of pioneering treatment methods that empower patients to take an active role in managing their health.

The company’s flagship investigational product is etripamil. This novel calcium channel blocker is formulated as a nasal spray, designed for patients to self-administer without medical supervision. Etripamil is undergoing clinical studies to evaluate its efficacy in treating symptomatic episodic attacks associated with Paroxysmal Supraventricular Tachycardia (PSVT) and Atrial Fibrillation with Rapid Ventricular Rate (AFib-RVR). These conditions are characterized by sudden-onset and recurrent episodes of rapid heart rate, which can be debilitating for patients.

Etripamil’s innovative delivery method as a nasal spray presents a significant shift from traditional treatments, potentially offering patients a more convenient and immediate option for managing their heart conditions. The ability for self-administration could reduce the need for emergency medical interventions, thereby improving the quality of life for patients and lessening the burden on healthcare systems.

Milestone Pharmaceuticals’ participation in the Jefferies Global Healthcare Conference underscores its ongoing commitment to engaging with the broader healthcare community and investors. These events are crucial for the company to showcase its advancements, discuss future plans, and foster relationships that could support the continued development and commercialization of its products.

The Jefferies Global Healthcare Conference is a significant event in the healthcare industry, bringing together a diverse group of stakeholders, including pharmaceutical companies, investors, and industry experts. The conference provides a platform for companies to present their latest innovations, share research findings, and discuss industry trends and challenges.

Milestone Pharmaceuticals’ representation at this conference, particularly through the Fireside Chat, will provide valuable insights into the company's strategic vision and ongoing efforts to address unmet needs in cardiovascular care. This engagement is expected to enhance the company’s visibility within the industry and among potential investors.

In conclusion, Milestone Pharmaceuticals Inc. remains at the forefront of developing groundbreaking cardiovascular treatments. Its participation in the upcoming Jefferies Global Healthcare Conference reflects its dedication to advancing patient care and its proactive engagement with the healthcare community and investors. The company’s pioneering product, etripamil, highlights its innovative approach to empowering patients in managing their heart conditions effectively.